MEDICAL DEVICES

CeloNova Announces New Strategic Direction Focused on Creating Partnership

CeloNova BioSciences, Inc. | April 08, 2022

CeloNova Announces

CeloNova BioSciences, Inc. developer and manufacturer of a portfolio of novel surfaced coated technologies, including the proprietary Polyzene™-F nanocoating, announced the strategic decision to focus its core business on creating partnership and co-development opportunities with medical device manufacturers seeking to optimize implant interaction within the body. The company's nanocoated innovation is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date.

"We are pleased to offer leading medical device manufacturers access to the unique clinical advantages of our Polyzene-F nanocoated technology that has clinically demonstrated low thrombosis, restenosis and inflammation with rapid healing effects," stated Carl St. Bernard, President and Chief Executive Officer of CeloNova. "This technology offers a significant benefit to companies seeking to improve the clinical performance of their implant technologies."

"I fully support CeloNova's new strategic direction which allows medical device manufacturers to benefit from long-term biocompatibility and thromboresistance of Polyzene-F. When my students and I set out to study the hemocompatibility of this inorganic polymer in our lab in Heidelberg Germany, we soon realized its potential to significantly limit a wide range of implant complications and being broadly applied in the human body and in biomedical devices."

Professor Dr. Michael Grunze, Former Chair and Professor (emeritus) at the Institute of Applied Physical Chemistry of the Ruprecht-Karls-University in Heidelberg and co-inventor of Polyzene-F

CeloNova is based on a rich history of medical innovation with two PzF coated medical implants successfully commercialized in the U.S. and the EU. The company's PzF coated embolic microspheres product line was sold to Boston Scientific in 2015 and the COBRA PzF NanoCoated Coronary Stent, was developed to safely and effectively treat patients who may benefit from 1-month of dual antiplatelet therapy.  CeloNova's new business direction builds upon the successful application of PzF in interventional oncology and cardiology and expands its opportunities through the development of new surface coating technologies to address important unmet clinical needs.

"In my pre-clinical research at CVPath since 2012, CeloNova's proprietary Polyzene-F coating has consistently demonstrated a unique advantage of allowing an implant to heal quickly and in a functional way, without the need for antiproliferative drug elution," stated Aloke Finn, MD, Medical Director and Chief Scientific Officer at CVPath and Associate Professor of Medicine at the University of Maryland. "I believe Polyzene-F will continue to play an important role in delivering safety and efficacy in clinical practice."

Polyzene-F is a proprietary, ultra-pure and highly elastic surface coating possessing unique mechanical properties that allow an implant to be coated at a nanoscale level. The coating acts as a biocompatible barrier between the implant, intimal surface and circulating elements in the blood and has demonstrated thromboresistant and anti-inflammatory properties with significantly faster, higher quality healing compared to market-leading technologies.1*

About CeloNova BioSciences, Inc.

CeloNova BioSciences, Inc. is a global medical device company that develops, manufactures and markets novel surfaced coated technologies, including its proprietary Polyzene™-F nanocoating. The next generation nanocoating is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date. 

Spotlight

How similar are President Obama's and Republican nominee Mitt Romney's two versions of mandated health insurance coverage? Check out this infographic to see where the policies overlap and diverge...

Spotlight

How similar are President Obama's and Republican nominee Mitt Romney's two versions of mandated health insurance coverage? Check out this infographic to see where the policies overlap and diverge...

Related News

HEALTH TECHNOLOGY, MEDICAL DEVICES

SimiTree Announces Afia and GreenpointMed Acquisition

SimiTree | January 13, 2023

SimiTree has strengthened its position in the US behavioral health support market by acquiring two new companies. On January 12, 2023, Bill Simione, CEO and Managing Principal of SimiTree, announced the acquisition of behavioral health data analytics and consulting firm Afia and Florida-based credentialing service provider GreenpointMed. This move enhances the full range of support services offered by SimiTree and its behavioral health flagship, Infinity Behavioral Health Services. Afia employs data-driven decision-making to address business challenges by streamlining EHR implementations, optimizing revenue cycles, promoting clinical best practices, and developing IT infrastructures to advance behavioral businesses. SimiTree's leading data analytics capabilities are enhanced by this acquisition, allowing clients to benefit from tech-enabled optimization of financial, clinical, and operational functions and gain greater insight from actionable data. Acquiring GreenpointMed has allowed SimiTree to expand billing and debt recovery capabilities and offer time-saving credentialing services with insurance panels to behavioral health providers. GreenpointMed has substantial credentialing experience in every state, with all insurers, including Medicare and Medicaid. "This move delivers the scalability SimiTree needs to address the behavioral health industry's growing need for our services as we head into 2023," said Bill Simone. He further added, "We remain committed to providing a robust array of services to assist behavioral health providers in developing a stronger revenue cycle with improved cash flow, higher collection rates, and best-in-class processes." (Source – PR Newswire) About SimiTree Formed by the merger of Simione Healthcare Consultants with BlackTree Healthcare Consulting in 2021, SimiTree provides clinical, financial, operational consulting and outsourced services such as review choice demonstration (RCD), OASIS, billing, coding, and quality assessment and performance improvement (QAPI). Headquartered in King of Prussia (Pennsylvania), the company aligns its teams, services, and approach with clients' challenges to help them improve operational performance, fulfill clinical and financial potential, and improve the organization's overall health.

Read More

DIGITAL HEALTHCARE

CipherHealth and SADA Collaborate to Improve Patient Care Via Looker

CipherHealth | January 06, 2023

CipherHealth, a leader in patient engagement technology and communication solutions, recently teamed up with SADA, an award-winning Google Cloud Partner, to use Google Cloud's Looker to collect socioeconomic data to improve patient care. With this new feature, CipherHealth aims to empower healthcare leaders by enabling them to collect large volumes of data and assist patients and medical professionals at each point of the care journey. Earlier, CipherHealth's platform gave doctors and nurses complete conversational and clinical information about each patient. It worked with SADA, a company that knows how to set up and run Google Cloud's analytics platform Looker, to add self-service analytics to the platform and make it more useful. With the help of Looker Embedded Analytics, CipherHealth has made it easier for its clients to access this data for analysis and visualization at any time during the patient's life. As a result of the partnership, CipherHealth's clients, which include 500 hospitals across the country, will now have access to patient data about social determinants of health (SDOH). Also, they can use in-built analytics to divide patient groups and send personalized messages to each of them separately. With this information, CipherHealth's clients can zero in on a specific patient and find out what kind of treatment they need, along with any special accommodations (like if they have trouble making appointments). CipherHealth is HIPAA-compliant, meaning it may safely analyze and transfer clients' protected health information (PHI) over the internet. The company believes combining SADA with Google Cloud can give its clients a new view of their patient populations. It will also allow the company to make changes to its care delivery that are good for patients. In line with this, SADA said that the integration of Looker from Google Cloud improves the patient experience for CipherHealth and its clients. About CipherHealth CipherHealth is a proven technology solutions partner dedicated to improving patient communication and care. Since 2009, the company has helped build the market for patient engagement by making innovative tools that help providers give excellent care. The range of patient engagement programs from CipherHealth sets new standards for care and provides healthcare businesses with the tools they need to have meaningful conversations with their patients.

Read More

HEALTH TECHNOLOGY, DIGITAL HEALTHCARE

KARL STORZ Receives Innovative Technology Designation from Vizient for TIPCAM1 Rubina with ARTip SOLO Robotic Assistance

KARL STORZ | December 21, 2022

KARL STORZ Endoscopy-America, Inc., proudly announces its TIPCAM®1 Rubina® with ARTip® SOLO robotic assistance has received an Innovative Technology designation from Vizient, Inc., the largest healthcare performance improvement company in the country. KARL STORZ exhibited TIPCAM1 Rubina with ARTip SOLO at the Vizient Innovative Technology Exchange on Oct. 17 in Dallas, Texas. Each year, healthcare experts serving on Vizient member-led councils review select products and technologies for their potential to enhance clinical care, patient safety, and healthcare worker safety or to improve business operations of healthcare organizations. Innovative Technology designations are awarded to previously contracted products to signal healthcare providers that these innovations can have a positive impact on patient care and business models. TIPCAM1 Rubina is the only advanced endoscopic solution on the market that gives surgeons access to the most sophisticated visualization technologies of 4K imaging in 2D, 3D, and NIR/ICG, all in one video endoscope using ONE system, the KARL STORZ IMAGE1™ S. The ARTip SOLO robotic camera guidance system, paired with the TIPCAM1 Rubina, allows the operating surgeon to maintain stability and precise control of the field of view. This improves the environment to train surgeons on technical skills, enabling them to operate alone—which can improve efficiency, thereby lowering overall costs. It also provides ideal ergonomics, especially in long procedures. Advanced technologies such as 4K 3D and 4K NIR/ICG provide the ability to visualize crucial details during surgery, often resulting in improved safety and outcomes. 3D has shown to improve task completion time by 64% and reduce errors by 63% especially where suturing is involved. NIR/ICG can reduce complication rates through assessment of blood flow and visualization of critical anatomy. Due to the complexities in surgery, having access to different tools can give a surgeon confidence to properly assess and create a safe surgical plan. The unique combination of the TIPCAM1 Rubina and ARTip SOLO allows hospitals to bridge the gap between robotics and laparoscopy by recreating a robotic experience, incorporating advanced technologies that deliver value without the large capital expense. “KARL STORZ is committed to delivering quality products to allow for optimal surgical flow and advanced patient care. Desirable patient outcomes and improved surgeon ergonomics and autonomy, along with ease of setup enhancing operating room workflow, are just a few of the benefits offered by this innovative endoscopic solution. The advancement in imaging with streamlined robotic assistance allows for use across multiple surgical specialties, in both hospital and ambulatory care settings in rural and urban patient populations, providing equitable access to health care.” Aarathi Cholkeri-Singh, MD, Medical Director at KARL STORZ Endoscopy-America, Inc “Healthcare experts on Vizient member councils evaluated TIPCAM1 Rubina with ARTip SOLO robotic assistance as part of the Innovative Technology Program,” said Kelly Flaharty, Vizient Senior Director of Contract Services. “This designation indicates TIPCAM1 Rubina with ARTip SOLO robotic assistance has one or more qualities that differentiate it from similar products and has potential to make an incremental improvement in healthcare. Congratulations to KARL STORZ.” KARL STORZ Endoscopy-America, Inc., proudly announces its TIPCAM®1 Rubina® with ARTip® SOLO robotic assistance has received an Innovative Technology designation from Vizient, Inc., the largest healthcare performance improvement company in the country. KARL STORZ exhibited TIPCAM1 Rubina with ARTip SOLO at the Vizient Innovative Technology Exchange on Oct. 17 in Dallas, Texas. Each year, healthcare experts serving on Vizient member-led councils review select products and technologies for their potential to enhance clinical care, patient safety, and healthcare worker safety or to improve business operations of healthcare organizations. Innovative Technology designations are awarded to previously contracted products to signal healthcare providers that these innovations can have a positive impact on patient care and business models. TIPCAM1 Rubina is the only advanced endoscopic solution on the market that gives surgeons access to the most sophisticated visualization technologies of 4K imaging in 2D, 3D, and NIR/ICG, all in one video endoscope using ONE system, the KARL STORZ IMAGE1™ S. The ARTip SOLO robotic camera guidance system, paired with the TIPCAM1 Rubina, allows the operating surgeon to maintain stability and precise control of the field of view. This improves the environment to train surgeons on technical skills, enabling them to operate alone—which can improve efficiency, thereby lowering overall costs. It also provides ideal ergonomics, especially in long procedures. Advanced technologies such as 4K 3D and 4K NIR/ICG provide the ability to visualize crucial details during surgery, often resulting in improved safety and outcomes. 3D has shown to improve task completion time by 64% (44 of 69 studies) and reduce errors by 63% (28 of 45 studies), especially where suturing is involved. NIR/ICG can reduce complication rates through assessment of blood flow and visualization of critical anatomy. Due to the complexities in surgery, having access to different tools can give a surgeon confidence to properly assess and create a safe surgical plan. The unique combination of the TIPCAM1 Rubina and ARTip SOLO allows hospitals to bridge the gap between robotics and laparoscopy by recreating a robotic experience, incorporating advanced technologies that deliver value without the large capital expense. “KARL STORZ is committed to delivering quality products to allow for optimal surgical flow and advanced patient care. Desirable patient outcomes and improved surgeon ergonomics and autonomy, along with ease of setup enhancing operating room workflow, are just a few of the benefits offered by this innovative endoscopic solution,” said Aarathi Cholkeri-Singh, MD, Medical Director at KARL STORZ Endoscopy-America, Inc. “The advancement in imaging with streamlined robotic assistance allows for use across multiple surgical specialties, in both hospital and ambulatory care settings in rural and urban patient populations, providing equitable access to health care.” “Healthcare experts on Vizient member councils evaluated TIPCAM1 Rubina with ARTip SOLO robotic assistance as part of the Innovative Technology Program,” said Kelly Flaharty, Vizient Senior Director of Contract Services. “This designation indicates TIPCAM1 Rubina with ARTip SOLO robotic assistance has one or more qualities that differentiate it from similar products and has potential to make an incremental improvement in healthcare. Congratulations to KARL STORZ.” About Vizient Vizient represents a diverse membership that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non-acute healthcare providers and represents approximately $130 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle. About KARL STORZ KARL STORZ Endoscopy-America, Inc. is an innovative leader in endoscopic technology and imaging solutions across virtually all surgical specialties. KARL STORZ provides solutions that facilitate operational and workflow efficiencies across various sites of care, so healthcare providers can deliver optimal patient care in the most cost-effective manner. The group is an affiliate of KARL STORZ SE & Co. KG, an international leader and family-owned company based in Tuttlingen, Germany, that designs, engineers, manufactures, and markets all its products with an emphasis on visionary design, precision craftsmanship, and clinical effectiveness.

Read More